Literature DB >> 23084527

Quality of life with advanced metastatic prostate cancer.

Matthew J Resnick1, David F Penson.   

Abstract

The health-related quality-of-life (HRQOL) implications of advanced metastatic prostate cancer are variable. There are several different HRQOL instruments that measure domains germane to patients with advanced metastatic disease. The burden of prostate cancer is inversely related to the magnitude of HRQOL declines. Treatment with androgen deprivation therapy commonly results in HRQOL declines that have served as the impetus for intermittent therapy. Conversely, chemotherapeutic agents have been associated with improvements in functional status for men with castrate-resistant disease. Emerging therapies may result in significant HRQOL improvements in this population, and careful prospective evaluation of patient-reported outcomes will be required.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23084527     DOI： 10.1016/j.ucl.2012.07.007

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.241


  8 in total

1.  Importance of and Satisfaction with Psychosocial Support among Cancer Patients and Survivors in Puerto Rico: Gender, Health Status, and Quality of Life Associations.

Authors:  Eida M Castro; Gloria Asencio; Gwendolyn P Quinn; Thomas Brandon; Clement K Gwede; Susan Vadaparampil; Vani Simmons; Jessica McIntyre; Julio Jiménez
Journal:  P R Health Sci J       Date:  2017-12       Impact factor: 0.705

2.  Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Authors:  Ingrid Lorese Tablazon; Lauren E Howard; Amanda M De Hoedt; William J Aronson; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Martha K Terris; Stephen J Freedland; Stephen B Williams
Journal:  Cancer       Date:  2019-08-07       Impact factor: 6.860

Review 3.  Implementation of patient-reported outcome measures into health care for men with localized prostate cancer.

Authors:  Udit Singhal; Ted A Skolarus; John L Gore; Matthew G Parry; Ronald C Chen; Julie Nossiter; Alan Paniagua-Cruz; Arvin K George; Paul Cathcart; Jan van der Meulen; Daniela A Wittmann
Journal:  Nat Rev Urol       Date:  2022-03-08       Impact factor: 16.430

Review 4.  Hormonal Therapy for Prostate Cancer.

Authors:  Kunal Desai; Jeffrey M McManus; Nima Sharifi
Journal:  Endocr Rev       Date:  2021-05-25       Impact factor: 19.871

Review 5.  Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes.

Authors:  Hamed Ahmadi; Siamak Daneshmand
Journal:  Patient Relat Outcome Meas       Date:  2014-07-05

6.  Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT).

Authors:  Suneil Jain; Gillian Prue; Malcolm Brown; Marie Murphy; Lauri McDermott; Helen McAneney; Joe M O'Sullivan
Journal:  Pilot Feasibility Stud       Date:  2019-08-16

7.  The Anxiety Depression Pathway Among Men Following a Prostate Cancer Diagnosis: Cross-Sectional Interactions Between Anger Responses and Loneliness.

Authors:  Simon M Rice; David Kealy; John S Ogrodniczuk; Zac E Seidler; Gabriela Montaner; Suzanne Chambers; John L Oliffe
Journal:  Am J Mens Health       Date:  2021 May-Jun

8.  Experiences of Australian men diagnosed with advanced prostate cancer: a qualitative study.

Authors:  Suzanne K Chambers; Melissa K Hyde; Kirstyn Laurie; Melissa Legg; Mark Frydenberg; Ian D Davis; Anthony Lowe; Jeff Dunn
Journal:  BMJ Open       Date:  2018-02-17       Impact factor: 2.692
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.